ArticlePloS one2017
A fresh look at polymicrobial bloodstream infection in cancer patients.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Clinical outcomes of antimicrobial resistance in cancer patients: a systematic review of multivariable models.BMC infectious diseases · 2023Pooled it
- Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2021Pooled it
- Neutropenic Enterocolitis and Sepsis: Towards the Definition of a Pathologic Profile.Medicina (Kaunas, Lithuania) · 2021Pooled it
- Risk factors for polymicrobial klebsiella pneumoniae bloodstream infection: a retrospective cohort study using the antimicrobial resistance monitoring database.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Bloodstream Infections in Solid Malignancies: Risk Factors, Resistance Patterns, and Clinical Outcomes from a Two-Center Cohort in Heraklion, Crete.Life (Basel, Switzerland) · 2026Article
- Evaluation of three rapid antimicrobial susceptibility testing methods directly from positive blood cultures integrated with rapid pathogen identification.BMC microbiology · 2026Article
- Clinical and microbiological characteristics of polymicrobial bloodstream infections in hematologic malignancy patients: a cross-sectional study.BMC infectious diseases · 2026Article
- 28-day all-cause mortality and associated factors in cancer patients with bacteremia at a peruvian referral center.PloS one · 2026Article
- Clinical and Microbiological Outcomes of Critically Ill Patients With Monomicrobial Versus Polymicrobial Bacterial Bloodstream Infections: A Retrospective Cohort Study.Open forum infectious diseases · 2025Article
- Impact of rapid identification by MALDI-TOF MS from positive blood cultures in Enterococcus spp. bloodstream infections.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Etiology, Risk Factors, and Outcomes of Bacteremia in Patients With Hematologic Malignancies and Febrile Neutropenia in Uganda.Open forum infectious diseases · 2024Article
- Multiplex microarray PCR Unyvero BCU system to accelerate relevant antimicrobial treatment in polymicrobial bloodstream infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Article
- Polymicrobial bloodstream infections per se do not increase mortality compared to monomicrobial bloodstream infections in sepsis patients: a Korean nationwide sepsis cohort study.BMC infectious diseases · 2024Article
- Bloodstream infections in cancer patients in central India: pathogens and trends of antimicrobial resistance over a 5-year period.Access microbiology · 2024Article
- Clinical characteristics and outcomes of persistent bacteremia in patients with head and neck cancer in a tertiary care hospital.Frontiers in medicine · 2024Article
- Evaluation of Blood Culture Results in Patients with Malignancy in Erzurum Province, Turkey.Acta medica Lituanic · 2024Article
- Blood culture identification (BCID) performance in polymicrobial bacteremia.Diagnostic microbiology and infectious disease · 2023Article
- Clinical characteristics of bloodstream infections in adult patients with solid tumours and a nomogram for mortality prediction: a 5-year case-controlled retrospective study in a tertiary-level hospital.Frontiers in cellular and infection microbiology · 2023Article
- A novel prognostic model for malignant patients with Gram-negative bacteremia based on real-world research.Scientific reports · 2022Observational
- Molecular Methodologies for Improved Polymicrobial Sepsis Diagnosis.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the current incidence, clinical features, risk factors, aetiology, antimicrobial resistance and outcomes of polymicrobial bloodstream infection (PBSI) in patients with cancer.
methodsAll prospectively collected episodes of PBSI in hospitalised patients were compared with episodes of monomicrobial bloodstream infection (MBSI) between 2006 and 2015.
resultsWe identified 194 (10.2%) episodes of PBSI and 1702 MBSI (89.8%). The presence of cholangitis, biliary stenting, neutropenia, corticosteroids, neutropenic enterocolitis and other abdominal infections were identified as risk factors for PBSI. Overall, Gram-negative organisms were the most frequent aetiology, but Enterococcus spp. were especially frequent causes of Gram-positive PBSI (30.8%). Multidrug-resistant (MDR) organisms were more commonly found in PBSI than in MBSI (20.6% vs 12.9%; p = 0.003). Compared to patients with MBSI, those with PBSI presented with higher early (15% vs 1.4%; p = 0.04) and overall (32% vs 20.9%; p<0.001) case-fatality rates. Risk factors for overall case-fatality were a high-risk MASCC (Multinational Association of Supportive Care in Cancer) index score, corticosteroid use, persistent bacteraemia and septic shock.
conclusionsPBSI is a frequent complication in patients with cancer and is responsible for high mortality rates. Physicians should identify patients at risk for PBSI and provide empiric antibiotic therapy that covers the most frequent pathogens involved in these infections, including MDR strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.